Nektar Therapeutics
Sep 6, 2017
PDF

Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 2017 Morgan Stanley Global Healthcare Conference in New York City

SAN FRANCISCO, Sept. 6, 2017 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming 2017 Morgan Stanley Global Healthcare Conference in New York City on Tuesday, September 12, 2017 at 12:55 p.m. Eastern Time.

The presentation will be accessible via a Webcast through a link posted on the Investor Events section of the Nektar website:  http://ir.nektar.com/events.cfm. This Webcast will be available for replay until October 10, 2017.

About Nektar

Nektar Therapeutics is a research-based development stage biopharmaceutical company whose mission is to discover and develop innovative medicines to address the unmet medical needs of patients. Our R&D pipeline of new investigational medicines includes treatments for cancer, auto-immune disease and chronic pain. We leverage Nektar's proprietary and proven chemistry platform in the discovery and design of our new therapeutic candidates. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

Contact:

Investors
Jennifer Ruddock of Nektar Therapeutics
415-482-5585 

 

View original content:http://www.prnewswire.com/news-releases/nektar-therapeutics-president-and-ceo-howard-w-robin-to-present-at-the-2017-morgan-stanley-global-healthcare-conference-in-new-york-city-300513908.html

SOURCE Nektar Therapeutics

News Provided by Acquire Media